Trikafta 50-25-37.5 MG/75 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCPF9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $73,831
Award facts
- Contract value 100% obligated
- $73,830.74 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $73,830.74 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 50-25-37.5 mg/75 mg tablets (84-count units). The award, issued January 6, 2026, with an ultimate completion date of January 7, 2026, represents a delivery against DMS Pharmaceutical Group's existing Indefinite Delivery Contract under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. No set-aside designation was applied to this award, demonstrating the contractor's competitive capability in unrestricted federal procurement.
This delivery order supports the Department of Defense's pharmaceutical supply chain requirements through DLA's Medical Supply Chain division. DMS Pharmaceutical Group holds a single-award IDC under the PPV-G GEN V program—a $30.3 billion government-wide acquisition strategy—with a contract ceiling of $499.999 billion and performance period extending through December 31, 2036. The contractor's established track record supplying diverse pharmaceutical products, including specialty biologics and branded medications, to military healthcare facilities positions it as a critical regional pharmaceutical supplier for DoD operations. Trikafta, a cystic fibrosis therapeutic, addresses specialized pharmaceutical requirements within the federal military medical system's formulary.
Quick answers
Who was awarded contract SPE2DR26FCPF9?
SPE2DR26FCPF9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FCPF9 worth?
The government has obligated $73,831 on SPE2DR26FCPF9.
Is contract SPE2DR26FCPF9 an order under another contract?
Yes. SPE2DR26FCPF9 is a delivery order under SPE2DR25D9131, an indefinite delivery contract.
Was contract SPE2DR26FCPF9 competed?
The extent of competition for SPE2DR26FCPF9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award